InteRNA Technologies and Dana-Farber Cancer Institute to Collaborate on the Role of microRNAs in Cancer Pathways

UTRECHT, The Netherlands, November 2 /PRNewswire/ — InteRNA Technologies
B.V. and the Dana-Farber Cancer Institute (Boston, USA) have entered into a
research agreement to develop microRNA (miRNA)-based therapeutics for cancer.

Under the research collaboration with Associate Professor William C.
Hahn, MD, PhD (Department of Medical Oncology), InteRNA’s unique
lentiviral-based miRNA overexpression library will be applied in
multi-parametric, high-throughput functional screening assays to identify the
biological role of individual miRNAs and novel therapeutic targets in diverse
cancer pathways.

“We are very excited about this collaboration with Dr. Hahn, a renowned
cancer investigator, and the Dana-Farber, as it allows for functional screens
in diverse cell based assays embedded in a lab with extensive knowledge of
cancer”, said Roel Schaapveld, Chief Executive Officer of InteRNA
Technologies.

“These functional screens hold great promise to help us better understand
the roles of miRNAs in cancer and to identify potential treatment targets,”
said Dr. Hahn of Dana-Farber Cancer Institute.

About InteRNA Technologies B.V.

InteRNA Technologies B.V. actively explores and exploits opportunities to
translate its unique collection of miRNAs and miRNA discovery and validation
technologies into successful diagnostic, prognostic and therapeutic
applications. The company’s primary focus is to unravel the role of its
proprietary miRNAs in cancer.

InteRNA Technologies was incorporated in 2006 by Aglaia Oncology Fund and
has established close relationships with the research groups of its founders

See for more information http://www.interna-technologies.com.

SOURCE InteRNA Technologies B.V.